Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

177Lu-DOTATATE for the treatment of gastroenteropancreatic neuroendocrine tumors
Satya Das, Taymeyah Al‐Toubah, Ghassan El‐Haddad, et al.
Expert Review of Gastroenterology & Hepatology (2019) Vol. 13, Iss. 11, pp. 1023-1031
Open Access | Times Cited: 92

Showing 1-25 of 92 citing articles:

177Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial
Jonathan Strosberg, Martyn Caplin, Pamela L. Kunz, et al.
The Lancet Oncology (2021) Vol. 22, Iss. 12, pp. 1752-1763
Closed Access | Times Cited: 183
Targeted α-Emitter Therapy with 212Pb-DOTAMTATE for the Treatment of Metastatic SSTR-Expressing Neuroendocrine Tumors: First-in-Humans Dose-Escalation Clinical Trial
Ebrahim S. Delpassand, Izabela Tworowska, Rouzbeh Esfandiari, et al.
Journal of Nuclear Medicine (2022) Vol. 63, Iss. 9, pp. 1326-1333
Open Access | Times Cited: 114
Peptide–drug conjugate-based novel molecular drug delivery system in cancer
Yishen Zhu, Kexing Tang, Jiayi Lv
Trends in Pharmacological Sciences (2021) Vol. 42, Iss. 10, pp. 857-869
Closed Access | Times Cited: 107
Radiopharmaceuticals: navigating the frontier of precision medicine and therapeutic innovation
Shivang Dhoundiyal, Shriyansh Srivastava, Sachin Kumar, et al.
European journal of medical research (2024) Vol. 29, Iss. 1
Open Access | Times Cited: 53
Peptide Drug Conjugates and Their Role in Cancer Therapy
Ethan Heh, Jesse Allen, Fabiola Ramirez, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 1, pp. 829-829
Open Access | Times Cited: 48
Peptide-drug conjugates: A new paradigm for targeted cancer therapy
Mo Wang, Jiawei Liu, Mingjing Xia, et al.
European Journal of Medicinal Chemistry (2024) Vol. 265, pp. 116119-116119
Closed Access | Times Cited: 32
Advances in peptide-based drug delivery systems
Sijie Guo, Jing Wang, Qi Wang, et al.
Heliyon (2024) Vol. 10, Iss. 4, pp. e26009-e26009
Open Access | Times Cited: 21
Peptide-Drug Conjugates: Design, Chemistry, and Drug Delivery System as a Novel Cancer Theranostic
Syed Faheem Askari Rizvi, Lin‐Jie Zhang, Haixia Zhang, et al.
ACS Pharmacology & Translational Science (2024) Vol. 7, Iss. 2, pp. 309-334
Open Access | Times Cited: 19
Targeted Alpha Therapy: Progress in Radionuclide Production, Radiochemistry, and Applications
Bryce J. B. Nelson, Jan Andersson, Frank Wuest
Pharmaceutics (2020) Vol. 13, Iss. 1, pp. 49-49
Open Access | Times Cited: 129
Drug conjugate-based anticancer therapy - Current status and perspectives
Yuqi Yang, Shuhang Wang, Peiwen Ma, et al.
Cancer Letters (2022) Vol. 552, pp. 215969-215969
Open Access | Times Cited: 68
Peptide-Drug Conjugates: A New Hope for Cancer Management
Vivek P. Chavda, Hetvi K. Solanki, Majid Davidson, et al.
Molecules (2022) Vol. 27, Iss. 21, pp. 7232-7232
Open Access | Times Cited: 60
Progress and Future Directions with Peptide-Drug Conjugates for Targeted Cancer Therapy
Jakob Lindberg, Johan Nilvebrant, Per‐Åke Nygren, et al.
Molecules (2021) Vol. 26, Iss. 19, pp. 6042-6042
Open Access | Times Cited: 59
Learn from antibody–drug conjugates: consideration in the future construction of peptide-drug conjugates for cancer therapy
Mo Wu, Wei Huang, Nan Yang, et al.
Experimental Hematology and Oncology (2022) Vol. 11, Iss. 1
Open Access | Times Cited: 40
Strategies to improve the physicochemical properties of peptide-based drugs
Michelle Felicia Lee, Chit Laa Poh
Pharmaceutical Research (2023) Vol. 40, Iss. 3, pp. 617-632
Closed Access | Times Cited: 36
Lutetium-177 PSMA for the treatment of metastatic castrate resistant prostate cancer: a systematic review
Kanchi Patell, Matthew Kurian, Jorge A. García, et al.
Expert Review of Anticancer Therapy (2023) Vol. 23, Iss. 7, pp. 731-744
Open Access | Times Cited: 25
Therapeutic proteins: developments, progress, challenges, and future perspectives
Vimal Kumar, Arti Barwal, Nitin Sharma, et al.
3 Biotech (2024) Vol. 14, Iss. 4
Closed Access | Times Cited: 12
Engineering peptide drug therapeutics through chemical conjugation and implication in clinics
Syed Faheem Askari Rizvi, Haixia Zhang, Quan Fang
Medicinal Research Reviews (2024) Vol. 44, Iss. 6, pp. 2420-2471
Closed Access | Times Cited: 11
Advancements in the development of radiopharmaceuticals for nuclear medicine applications in the treatment of bone metastases
Michael R. Dyer, Zhenghan Jing, Kathleen Duncan, et al.
Nuclear Medicine and Biology (2024) Vol. 130-131, pp. 108879-108879
Closed Access | Times Cited: 9
Gastroenteropancreatic neuroendocrine neoplasms: current development, challenges, and clinical perspectives
Xianbin Zhang, Yibao Fan, Rui Jing, et al.
Military Medical Research (2024) Vol. 11, Iss. 1
Open Access | Times Cited: 9
A phase I/II study of the safety and efficacy of [177Lu]Lu-satoreotide tetraxetan in advanced somatostatin receptor-positive neuroendocrine tumours
Damian Wild, Henning Grønbæk, Shaunak Navalkissoor, et al.
European Journal of Nuclear Medicine and Molecular Imaging (2023) Vol. 51, Iss. 1, pp. 183-195
Open Access | Times Cited: 20
Current clinical application of lutetium‑177 in solid tumors (Review)
Tingting Niu, Fan Mi, Binwei Lin, et al.
Experimental and Therapeutic Medicine (2024) Vol. 27, Iss. 5
Open Access | Times Cited: 8
Risk of Bowel Obstruction in Patients with Mesenteric or Peritoneal Disease Receiving Peptide Receptor Radionuclide Therapy
Jonathan Strosberg, Taymeyah Al‐Toubah, Eleonora Pellè, et al.
Journal of Nuclear Medicine (2020) Vol. 62, Iss. 1, pp. 69-72
Open Access | Times Cited: 44
The Management of Phaeochromocytomas and Paragangliomas in the Era of Precision Medicine: Where Are We Now? Evidence-Based Systemic Treatment Options and Future Cluster Oriented Perspectives
Alessandra Bracigliano, Antonella Lucia Marretta, Luigi Pio Guerrera, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 3, pp. 354-354
Open Access | Times Cited: 5
Dosimetry and pharmacokinetics of [177Lu]Lu-satoreotide tetraxetan in patients with progressive neuroendocrine tumours
Seval Beykan Schürrle, Uta Eberlein, C. Ansquer, et al.
European Journal of Nuclear Medicine and Molecular Imaging (2024) Vol. 51, Iss. 8, pp. 2428-2441
Open Access | Times Cited: 5
An Insight into the Pharmacology of Sulphur Containing Peptide Drugs
Anamika Sharma, Lakhwinder Singh
European Journal of Medicinal Chemistry (2024) Vol. 271, pp. 116456-116456
Closed Access | Times Cited: 5
Page 1 - Next Page

Scroll to top